Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

0 SAR
Checkout

Overview

In this compelling video, Professor Vimal discusses the persistent unmet medical needs in Atopic Dermatitis (AD), highlighting that despite the availability of advanced therapies, many patients remain uncontrolled and unsatisfied with current treatment options. He underscores the growing demand for more targeted biologics and introduces Ebglyss, a newly approved IL-13 inhibitor for patients with moderate to severe AD aged 12 and above.

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Enhance awareness and clinical understanding among targeted healthcare professionals regarding Atopic Dermatitis (AD) and the differentiated role of Ebglyss (lebrikizumab) in the management of moderate-to-severe AD.

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LK-SA-0064

Related Classes